Presidential Perspectives: The Evolution and Future of NET Care

This episode of NETcast features a "presidential panel" of three distinguished NANETS leaders: Dr. Jennifer Chan (president 2025, Dana-Farber), Dr. Simran Singh (incoming president, Sunnybrook), and Dr. Thorvardur Halfdanarson (president emeritus, Mayo Clinic). The discussion covers transformative developments in NET management over the past decade, including radiopharmaceuticals, targeted therapies, and the recognition that NETs may be less rare than previously thought. The experts explore the future of alpha and beta particle therapy retreatment protocols, challenges in biomarker development, and the importance of treatment sequencing given disease heterogeneity. The panel also discusses the importance of mentorship and the welcoming nature of the NET community in nurturing early-career researchers, while acknowledging that future progress will likely come through incremental advances and optimal treatment sequencing rather than single breakthrough therapies.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.